Does Applied Genetic Technologies Corporation (AGTC) Have Any Gas After Today’s Significant Increase?

April 17, 2018 - By Linda Rogers

Applied Genetic Technologies Corporation (NASDAQ:AGTC) Logo

Investors sentiment decreased to 0.55 in 2017 Q4. Its down 0.02, from 0.57 in 2017Q3. It dropped, as 10 investors sold Applied Genetic Technologies Corporation shares while 21 reduced holdings. 10 funds opened positions while 7 raised stakes. 6.64 million shares or 2.25% less from 6.79 million shares in 2017Q3 were reported.
Royal Retail Bank Of Canada has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Bancshares Of New York Mellon Corp has 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 11,130 shares. 3,268 are held by Wells Fargo & Company Mn. Panagora Asset Mgmt holds 69,394 shares. Ancora Advisors Limited Liability Company holds 0% or 20,000 shares. Vanguard Grp Inc has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Ajo Lp reported 405,297 shares. Matarin Cap Mgmt Lc invested 0.01% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). 20,573 are held by Northern Tru. Dafna Cap Mngmt Ltd Liability owns 421,000 shares or 0.82% of their US portfolio. Acadian Asset Management Ltd Liability reported 679,152 shares. Susquehanna Interest Llp has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Renaissance Technologies Ltd Limited Liability Company has 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Macquarie Grp Ltd owns 11,258 shares. Citadel Advsrs Lc owns 16,533 shares or 0% of their US portfolio.

The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) is a huge mover today! The stock increased 10.20% or $0.5 during the last trading session, reaching $5.4. About 196,730 shares traded or 85.07% up from the average. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has declined 39.42% since April 17, 2017 and is downtrending. It has underperformed by 50.97% the S&P500.
The move comes after 8 months positive chart setup for the $97.77 million company. It was reported on Apr, 17 by Barchart.com. We have $5.67 PT which if reached, will make NASDAQ:AGTC worth $4.89 million more.

Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on May, 9. They expect $-0.25 EPS, down 400.00 % or $0.20 from last year’s $-0.05 per share. After $-0.29 actual EPS reported by Applied Genetic Technologies Corporation for the previous quarter, Wall Street now forecasts -13.79 % EPS growth.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company has market cap of $97.77 million. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It currently has negative earnings. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: